ArticleMicrobiology spectrum2026
The segmented flavivirus ALSV-encoded nucleoprotein VP2 inhibits type I interferon production by targeting RIG-I.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The Alongshan virus (ALSV), a newly identified tick-borne segmented flavivirus, can infect humans and cause Alongshan fever, making it imperative to understand its pathogenic mechanisms for the development of effective intervention strategies. Our previous research has established that ALSV exhibits sensitivity to interferon-beta (IFN-β) while having evolved the ability to antagonize downstream antiviral responses induced by type I IFN (IFN-I); however, the specific effects and underlying mechanisms by which ALSV modulates IFN-I production remain poorly understood. In the present study, we demonstrated that ALSV infection significantly suppresses host IFN-I production triggered by poly(I:C), a synthetic analog of viral double-stranded RNA that activates innate immune pathways. To unravel the molecular basis of this suppression, we systematically evaluated the impact of individual ALSV viral proteins on Toll-like receptor-mediated IFN-I production, revealing a complex regulatory network wherein distinct viral proteins target specific signaling molecules: specifically, VP2 and VP3 were found to be responsible for inhibiting RIG-I-mediated IFN-I production, while NSP2 and VP1b were identified as key inhibitors of MDA5-mediated IFN-I production, highlighting the virus's strategy of employing multiple proteins to disrupt innate immune signaling. Focusing further on the viral nucleoprotein VP2, we determined that it acts at the upstream signaling level of TANK-binding kinase 1, a critical kinase in the IFN-I signaling cascade. Mechanistically, VP2 directly interacts with RIG-I and mediates its degradation through an autophagy-dependent pathway, thereby impairing the host's ability to detect viral RNA and initiate IFN-I production. These findings not only expand our understanding of the immune evasion mechanisms employed by novel segmented flaviviruses but also offer valuable insights that could facilitate the development of new preventive and therapeutic strategies for the ALSV infection.IMPORTANCEAlongshan virus (ALSV) is an emerging segmented flavivirus that poses a growing threat to human and animal health across Eurasia. Despite its demonstrated capacity to infect humans and suppress interferon (IFN)-mediated antiviral responses, the precise mechanisms of ALSV immune evasion remain largely undefined. This study identifies the viral nucleoprotein VP2 as a key antagonist of host type I IFN (IFN-I) production. By directly interacting with and promoting the autophagy-mediated degradation of RIG-I, VP2 effectively disrupts innate immune recognition and signaling. This finding not only elucidates a previously unknown mechanism of immune suppression by ALSV but also highlights the virus's sophisticated strategy of using multiple proteins to selectively target RIG-I and MDA5 pathways. These insights advance our understanding of segmented flavivirus-host interactions and suggest that restoring RIG-I function may be a promising therapeutic strategy against ALSV infection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.